LRMR
Larimar Therapeutics, Inc.Company Information
- Company Name
- Larimar Therapeutics, Inc.
- CIK
- CIK0001374690
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- LRMR: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- LRMR
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-07-06
- Last sale
- —
- Shares purchased (TTM)
- 14,535,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 95,488,706
- Shares outstanding
- 103,882,937
- Ownership
- 91.92%
Earnings Market Reaction
- Filing date
- 2026-08-04
- Price on filing date
- —
- 1-month reaction
- -2.43%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 93 | 178 | 85 | 90 | 21 | 21 | 33 | 35 | 32 | 110 | 27 | 39 | ||||||
| Available For Sale Securities Debt Securities Current | 64 | 22 | 51 | 85 | 118 | 136 | 150 | 169 | 194 | 117 | 60 | 57 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 5 | 5 | 8 | 7 | 8 | 12 | 10 | 5 | 4 | 3 | 3 | ||||||
| Assets Current | 161 | 205 | 142 | 183 | 146 | 165 | 195 | 213 | 231 | 231 | 90 | 98 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | - | - | - | - | - | - | - | - | - | 12 | - | - | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Right Of Use Asset | 3 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Restricted Cash Noncurrent | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Other Assets Noncurrent | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets | 165 | 209 | 146 | 187 | 150 | 170 | 200 | 219 | 237 | 248 | 96 | 104 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 8 | 9 | 5 | 11 | 4 | 2 | 2 | 2 | 3 | 2 | 1 | 1 | ||||||
| Accrued Liabilities Current | 25 | 38 | 58 | 33 | 21 | 19 | 21 | 14 | 17 | 10 | 7 | 5 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 34 | 48 | 65 | 45 | 27 | 22 | 24 | 16 | 21 | 13 | 10 | 7 | ||||||
| Operating Lease Liability Noncurrent | 4 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | ||||||
| Liabilities | 38 | 50 | 68 | 48 | 30 | 26 | 28 | 21 | 26 | 17 | 14 | 11 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 625 | 622 | 513 | 511 | 444 | 443 | 441 | 438 | 436 | 434 | 270 | 268 | ||||||
| Retained Earnings Accumulated Deficit | -497 | -464 | -435 | -372 | -325 | -298 | -269 | -240 | -225 | -203 | -189 | -176 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | ||||||
| Stockholders Equity | 127 | 158 | 78 | 139 | 120 | 144 | 172 | 198 | 211 | 231 | 82 | 93 | ||||||
| Liabilities And Stockholders Equity | 165 | 209 | 146 | 187 | 150 | 170 | 200 | 219 | 237 | 248 | 96 | 104 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 215 | 115 | 115 | 115 | 115 | 115 | 115 | 115 | 115 | 115 | 115 | 115 | ||||||
| Common Stock Shares Issued | 104 | 104 | 83 | 86 | 64 | 64 | 64 | 64 | 64 | 64 | 44 | 44 | ||||||
| Shares Outstanding | 104 | 104 | 83 | 86 | 64 | 64 | 64 | 64 | 64 | 64 | 44 | 44 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLarimar Therapeutics, Inc. (LRMR) — SEC Financial Statements & Analysis
Larimar Therapeutics, Inc. (LRMR) is a pharmaceutical preparations company, incorporated in DE. Larimar Therapeutics, Inc. trades on Nasdaq as: LRMR. Larimar Therapeutics, Inc. (LRMR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04. Based on that filing, Larimar Therapeutics, Inc. carries a market cap of $316.84M, a P/E ratio of -1.84x, a P/B ratio of 2.49x, an enterprise value of $224.16M, and an EV/EBITDA multiple of -1.25x. On profitability, it posts a Return on Equity (ROE) of -139.63%, a Return on Assets (ROA) of -109.49%, and a Return on Invested Capital (ROIC) of -267.22%. Per share, it reports EPS of $-1.66, diluted EPS of $-1.66, free cash flow per share of $-0.85, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 72.98% year-over-year and EPS growth of 6.61% year-over-year. On the balance sheet, it maintains a current ratio of 4.70x, a quick ratio of 4.57x, working capital of $126.51M, a debt-to-equity ratio of 0.30x, a debt ratio of 0.23, free cash flow of $-88.80M (TTM), and net debt of $-92.69M. Figures sourced from SEC EDGAR.
- Market Cap
- $316.84M
- P/E TTM
- -1.84x
- EPS TTM
- $-1.66
- P/B TTM
- 2.49x
- ROE TTM
- -139.63%
- ROA TTM
- -109.49%
- Debt To Equity
- 0.30x
- Free Cash Flow TTM
- $-88.80M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Larimar Therapeutics, Inc. in?
Larimar Therapeutics, Inc. (LRMR) operates in the Pharmaceutical Preparations industry.
What exchange does LRMR trade on?
Larimar Therapeutics, Inc. (LRMR) trades on the Nasdaq.
Where is Larimar Therapeutics, Inc. incorporated?
Larimar Therapeutics, Inc. is incorporated in DE.
When was Larimar Therapeutics, Inc. (LRMR)'s most recent SEC filing?
Larimar Therapeutics, Inc. (LRMR)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-04.
What is LRMR's market cap?
Larimar Therapeutics, Inc. (LRMR) has a market capitalization of $316.84M as of 2026-06-30.
What is LRMR's EPS (earnings per share)?
Larimar Therapeutics, Inc. (LRMR)'s trailing twelve month EPS is $-1.66 as of 2026-06-30.
What is LRMR's ROE (return on equity)?
Larimar Therapeutics, Inc. (LRMR)'s trailing twelve month Return on Equity (ROE) is -139.63% as of 2026-06-30.
What is LRMR's ROA (return on assets)?
Larimar Therapeutics, Inc. (LRMR)'s trailing twelve month Return on Assets (ROA) is -109.49% as of 2026-06-30.
What is LRMR's ROIC (return on invested capital)?
Larimar Therapeutics, Inc. (LRMR)'s trailing twelve month Return on Invested Capital (ROIC) is -267.22% as of 2026-06-30.
What is LRMR's EV/EBITDA?
Larimar Therapeutics, Inc. (LRMR)'s trailing twelve month EV/EBITDA is -1.25x as of 2026-06-30.